

AD _____

Award Number: DAMD17-01-1-0344

TITLE: Identification and characterization of factors that affect estrogen receptor transcriptional activation in breast cancer

PRINCIPAL INVESTIGATOR: Laura M. Engle
Michael J. Garabedian, Ph.D.

CONTRACTING ORGANIZATION: New York University
School of Medicine
New York, New York 10016

REPORT DATE: July 2002

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030317 023

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for maintaining reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2002		3. REPORT TYPE AND DATES COVERED Annual Summary (1 July 2001 - 30 June 2002)	
4. TITLE AND SUBTITLE Identification and characterization of factors that affect estrogen receptor transcriptional activation in breast cancer				5. FUNDING NUMBER DAMD17-01-1-0344	
6. AUTHOR(S) Laura M. Engle Michael J. Garabedian, Ph.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) New York University School of Medicine New York, New York 10016 email - garabm01@med.nyu.edu				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Nearly half of human breast cancers are dependent on estrogen for growth. How estrogens stimulate cell growth is not understood. Estrogens activate an intracellular protein, the estrogen receptor (ER), which acts together with certain receptor-interacting proteins to "switch on" some genes involved in cellular proliferation. The goal of this project is to identify and elucidate the roles of such receptor-interacting proteins in ER function. I have identified three proteins that interact with the ER using the yeast two-hybrid system, including the Vitamin D receptor-interacting protein 150 (DRIP150), subunit of a nuclear receptor coactivator complex. I am currently defining the effects of DRIP150 on ER transcriptional activity using a transient transfection system designed to monitor ER-dependent transcriptional activation.					
14. SUBJECT TERMS estrogen receptor, coactivators, DRIP150, transcriptional regulation					15. NUMBER OF PAGES 6
					16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited		

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4-5
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	6
References.....	
Appendices.....	

Introduction

The estrogen receptor alpha (ER) is a ligand-dependent transcription factor, which is involved in activation of genes involved in cellular proliferation. Estrogen receptor activation has been shown to be a factor in the progression of nearly half of all human breast cancers. The mechanism by which ER interacts with cellular factors that mediate transcriptional activation is therefore an important target for breast cancer therapy and prevention which is in need of further characterization.

ER is a ligand-dependent transcription factor. In the absence of hormone, ER exists as an aporeceptor complex which, upon ligand binding, dissociates from the complex and binds as a dimer to estrogen response elements on the DNA, mediating transcriptional initiation of estrogen-responsive genes. Activation of these genes by ER is thought to be regulated by coactivator proteins. These factors interact with ER via two transcriptional activation domains: an N-terminal hormone-independent activation domain termed AF-1 and a C-terminal hormone-dependent activation domain termed AF-2. Recruitment of accessory proteins to these domains is responsible for regulation of transcriptional activation by ER.

The inactivation of ER is the currently the primary method of treatment for ER-positive breast cancers. The identification of ER associated coactivator proteins that affect ER function is therefore important in elucidating the molecular mechanisms involved in ER-positive breast cancer development and may become important targets for intervention and therapy. The purpose of this study is to isolate these factors using a yeast two-hybrid approach and to characterize their effects on ER transcriptional regulation.

Body


The purpose of this study is to isolate and characterize factors that regulate ER transcriptional activation through a yeast two-hybrid screen of random HeLa cell cDNAs. Seventy-four clones have been identified which interact with wild-type ER alpha. Three of these clones have been chosen for further characterization.

The first of these, designated hERT A1 (human Estrogen Receptor Trap) encodes a portion of a protein which was originally isolated as a topoisomerase II-binding protein with homology to the cell-cycle regulators Rad4 and Cut5 as well as the DNA repair enzyme XRCC1. High levels of topoisomerase II expression have been shown to correlate with extremely proliferative mammary carcinomas and repression of hormone receptor expression. Topoisomerase II-binding protein may

therefore be involved in ER repression by topoisomerase II in these aggressive tumors. This clone interacts strongly in a ligand-dependent manner with the AF-2 domain of ER and weakly in the hormone-independent manner with the AF-1 domain.

The second clone, designated hERT A2, has sequence homology to a portion of a human 82 kDa acidic protein in the EST database. Similar to hERT A1, the full-length hERT A2 protein interacts strongly in a ligand-dependent manner with the AF-2 domain of ER and weakly in the hormone-independent manner with the AF-1 domain. When overexpressed by transient transfection in a U2-OS osteosarcoma cell line, hERT A2 increases ER-dependent transcriptional activation by at least two-fold in the presence of estradiol.

Another clone that we have shown to interact with ER is the Vitamin D receptor-interacting protein 150 (DRIP150), a subunit of the DRIP coactivator complex. Overexpression of DRIP150 increases ER transcriptional activation. We have focusing our efforts on DRIP150 and its role in ER transcriptional regulation.



Differential regulation of ER α and ER β by DRIP150.

HeLa cells (1.2×10^5 cells/35 mm dish) were transiently transfected using Lipofectamine with paired receptor (0.2 μ g/dish) and reporter constructs (0.1 μ g/dish) for ER α and ER β + XETL along with the indicated amount of DRIP150 or empty expression vector to equalize the total amount of DNA per dish and 0.05 μ g pCMV-LacZ per dish as an internal control for transfection efficiency. Cells were treated with 10 nM 17 β -estradiol (E2) or the ethanol vehicle for 12 h and receptor transcriptional activation was assayed, normalized to β -galactosidase activity and expressed as relative luminescence units (RLU). The average of three independent experiments and standard error is shown.

Key research accomplishments

- Identified DRIP150 as a ER interacting protein
- Demonstrated that DRIP150 increases ER transcriptional activation

Reportable outcomes

None

Conclusion

We have identified DRIP150 as a protein that interacts with the ER and increases ER transcriptional activity when overexpressed. Identification of DRIP150 as a potential ER coactivator may offer a potential new target for turning off ER-dependent transcriptional activation and thereby inhibiting breast cancer growth.